计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A413911-5mg |
5mg |
现货 ![]() |
| |
| A413911-25mg |
25mg |
现货 ![]() |
| |
| A413911-50mg |
50mg |
现货 ![]() |
| |
| A413911-100mg |
100mg |
现货 ![]() |
| |
| A413911-250mg |
250mg |
现货 ![]() |
| |
| A413911-1g |
1g |
现货 ![]() |
|
| 别名 | 阿卡替尼 | 4-[8-氨基-3-[(2S)-1-(1-氧代-2-丁炔-1-基)-2-吡咯烷基]咪唑并[1,5-A]吡嗪-1-基]-N-2-吡啶基-苯甲酰胺 | 阿卡替尼(ACP-196) |
|---|---|
| 英文别名 | BDBM50175583 | Benzamide, 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl- | s8116 | Acalabrutinib [USAN:INN] | Acalabrutinib (JAN/USAN/INN) | Benzamide, 4-(8-amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrol |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Acalabrutinib (ACP-196) |
| 生化机理 | Acalabrutinib(ACP-196)是一种选择性第二代布鲁顿酪氨酸激酶(BTK)抑制剂,其 IC50 值为 3 nM,可阻止 B 细胞抗原受体(BCR)信号通路的激活。与伊布替尼相比,ACP-196 的靶向特异性更强,对其他 TEC 激酶家族成员(ITK、TXK、BMX 和 TEC)的选择性分别为 323 倍、94 倍、19 倍和 9 倍,而对表皮生长因子受体(EGFR)没有活性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 酪氨酸蛋白激酶 BTK 抑制剂 |
| 产品介绍 |
Acalabrutinib (ACP-196) 是选择性的第二代BTK抑制剂,抑制B细胞表面原抗体信号通路的激活,IC50为3 nM。它具有很好的靶标特异性,对BTK的选择性比对其他TEC激酶家族成员如ITK、TXK、BMK和TEC的选择性高323-, 94-, 19-, 9-倍。对EGFR没有活性。 Information Acalabrutinib (ACP-196) Acalabrutinib (ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 3 nM, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. ACP-196 has improved target specificity over ibrutinib with 323-, 94-, 19- and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR. Targets BTK (in a human whole-blood CD69 B cell activation assay) 3nM In vitro In the in vitro signaling assay on primary human CLL cells, acalabrutinib inhibits tyrosine phosphorylation of downstream targets of ERK, IKB, and AKT. Acalabrutinib demonstrates higher selectivity for BTK with IC50 determinations on nine kinases with a cysteine residue in the same position as BTK. Importantly, unlike ibrutinib, acalabrutinib does not inhibit EGFR, ITK, or TEC. acalabrutinib has no effect on EGFR phosphorylation on tyrosine residues Y1068 and Y1173. Compared with ibrutinib, acalabrutinib has much higher IC50(>1000 nM) or virtually no inhibition on kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1. In vivo oral administration of ACP-196 in mice results in dose-dependent inhibition of anti-IgM-induced CD86 expression in CD19+ splenocytes with an ED50 of 0.34 mg/kg compared to 0.91 mg/kg for ibrutinib. A similar model is used to compare the duration of Btk inhibition after a single oral dose of 25 mg/kg. ACP-196 inhibits CD86 expression >90% at 3h postdose. Cell Research(from reference) Cell lines:primary human CLL cells,T cells, NK cells, and epithelial cells |
| 纯度 | ≥98% |
| ALogP | 2.699 |
|---|---|
| hba_count | 5 |
| HBD Count | 2 |
| Rotatable Bond | 5 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488202174 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide |
| INCHI | 1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1 |
| InChi Key | WDENQIQQYWYTPO-IBGZPJMESA-N |
| Smiles | CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5 |
| Isomeric SMILES | CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5 |
| 分子量 | 465.51 |
| Reaxy-Rn | 33023407 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=33023407&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 93 mg/mL (199.78 mM); Ethanol: 60 mg/mL (128.89 mM); Water: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 93 |
| DMSO(mM) Max Solubility | 199.7808855 |
| Water(mg / mL) Max Solubility | <1 |
| 熔点 | >133°C |
| 分子量 | 465.500 g/mol |
| XLogP3 | 3.000 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 4 |
| 精确质量Exact Mass | 465.191 Da |
| 单同位素质量Monoisotopic Mass | 465.191 Da |
| 拓扑极表面积Topological Polar Surface Area | 119.000 Ų |
| 重原子数Heavy Atom Count | 35 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 845.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS08 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H373: 通过长时间或反复暴露对器官造成损害 |
| 预防措施声明 |
P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。 P501: 将内容物/容器处理到。。。 P319: 如果你感到不适,请寻求医疗帮助。 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | A413911 | |
| 分析证书 | A413911 | |
| 分析证书 | A413911 | |
| 分析证书 | A413911 | |
| 分析证书 | A413911 | |
| 分析证书 | A413911 | |
| 分析证书 | A413911 | |
| 分析证书 | A413911 | |
| 分析证书 | A413911 | |
| 分析证书 | A413911 | |
| 分析证书 | A413911 | |
| 分析证书 | A413911 |
| 1. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR et al.. (2016) Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.. N Engl J Med, 374 (4): (323-32). [PMID:26641137] |
| 2. Wu J, Zhang M, Liu D. (2016) Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.. J Hematol Oncol, 9 (21). [PMID:26957112] |
| 3. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P et al.. (2019) Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.. Blood Adv, 3 (9): (1553-1562). [PMID:31088809] |
| 4. Sharman JP, Banerji V, Fogliatto LM, Herishanu Y, Munir T, Walewska R, Follows G, Karlsson K, Ghia P, Corbett G et al.. (2019) ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL).. Blood, 134 (Supplement_1): (31). [PMID:31724010] |